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Abstract
Type 1 diabetes (T1D) is an autoimmune disease characterised by multiple defects of immune cells which 
allow the expansion of pathogenic β cell-specific T effector cells and subsequent T1D development. We performed 
immunomonitoring assays on blood immune cells in T1D children, their siblings and controls with the supposition 
that the results would elucidate the sequence of abnormalities in peripheral immune cells leading to the progression 
of autoimmunity from non-diabetic siblings to diabetic children. We assessed myeloid dendritic cell (MDC), 
plasmacytoid (P)DC, monocyte, CD4+T and CD8+T cell compartments, and cytokine expression in CD4+T cells 
and CD8+T cells, by polychromatic flow cytometry in erythrocyte-lysed fresh blood. The numbers of CD16+MDC, 
PDC and CD16+ monocytes were similarly decreased in diabetic children and their siblings. Whereas the numbers 
of CD16-CD141-MDC, CD16-CD141+MDC, CD16- monocytes, T naïve (CD45RO-CD62L+), T central memory 
(CD45RO+CD62L+), T effector memory (CD45RO+CD62L-), T terminally-differentiated effector (CD45RO-
CD62L-) and T regulatory cells (CD4+CD25+127lo/- or CD4+Foxp3+ cells) were not affected in diabetic children or 
their siblings. Furthermore, analysis of cytokine expression in CD4+T cells and CD8+T cell revealed an increased 
proportion of CD4+T cells expressing IL-17, differentiating diabetic children from their non-diabetic siblings. 
Our data suggest that diabetic children and their siblings suffer a considerable reduction of blood immune cells 
involving CD16+MDC, PDC and CD16+ monocytes that may result from shared genetic or environmental factors. 
However, this reduction of blood immune cells requires combination with the proinflammatory cytokine IL-17 to 
allow disease expression in diabetic children. 
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Introduction
Type 1 diabetes (T1D) is an autoimmune disease characterised by 
the expansion of pathogenic T effector cells which cause the irreversible 
destruction of insulin producing β cells [1]. However, these pathogenic 
T effector cells are not restricted to diabetic subjects, as they also persist 
in non-diabetic healthy controls [2]. It is believed that in healthy 
controls, peripheral tolerance mechanisms limit the pathogenic T 
effector cells whereas in diabetic subjects multiple immune defects 
breakdown this peripheral tolerance, permitting pathogenic T effector 
cell mediated T1D development [1]. 
Much of our understanding of peripheral immune cell defects in 
T1D comes from studies employing the non-obese diabetic (nOD) 
mouse model of T1D [1]. However, determining peripheral immune 
cell defects contributing to the development of T1D in humans 
remains a challenging task. The most promising approach in dentifying 
these defects is by directly comparing the blood immune cells from 
diabetic and non-diabetic subjects [2,3]. In particular, comparing 
diabetic patients with their non-diabetic siblings can provide major 
insight into disease specific defects as environmental factors and 
specific susceptibility genes are shared between these two groups [4]. 
Such studies can identify peripheral immune cell defects which are 
common to diabetic patients and their siblings, and as such, may result 
from shared genetic or environmental factors, as well as those that are 
disease specific. 
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It has been proposed that dysregulation of the number and/or 
function of CD11c+ myeloid dendritic cells (MDC) and monocytes, 
which also express β cell-autoantigen [5], favors the differentiation 
and expansion of pathogenic T effector cells and/or results in failure 
to induce an effective T regulatory (TReg) cell response [6].  Interest 
has, therefore, been focused on the characterisation of blood MDC, 
plasmacytoid (P)DC and TReg cells in separate cohorts of diabetic 
subjects. However, such studies have produced discrepant results. In 
recent-onset T1D patients, increased blood MDC and PDC numbers 
have been reported relative to established T1D patients and controls 
[7], whereas other studies have shown no difference in the numbers 
of blood MDC and PDC between adult subjects with established 
T1D and age-matched controls [8]. We have previously reported that 
diabetic children, aged 2-10 years, exhibit a marked decrease in blood 
MDC and PDC numbers whereas this difference was less obvious 
when comparing older cohorts [3]. This finding of decreased MDC 
and PDC numbers in both recent-onset and established T1D subjects 
was interpreted as a primary manifestation of T1D [3]. A decreased 
number of TReg cells has also been reported in children with recent-
onset TID, adults with established T1D and in the offspring of parents 
who carry the high risk human leukocyte antigen (HLA) alleles 
[9,10], Other studies have found comparable TReg cell populations in 
adults with established T1D and HLA /age-matched controls [11-13]. 
These differences between the reported blood DC and TReg numbers 
may result from different experimental conditions (e.g. study of 
erythrocyte-lysed fresh blood samples [3,13] versus Ficoll-density 
gradient isolated blood mononuclear cells [7-12] or superficial analyses 
(e.g. restricted surface markers for identifying DC and TReg cells, 
constraints of three- to four-color flow cytometry). In light of these 
limitations and the associated potential for data misinterpretation, 
continuing efforts are required to re-evaluate blood DC and TReg cell 
populations in diabetic and non-diabetic subjects. It is anticipated that 
ongoing immune activation induced by an array of proinflammatory 
cytokines produced by DC and monocytes [14-16] results in constant 
recruitment of  CD4+T and CD8+T cells from the T naïve (Tn) and T 
central memory (TCM) pools into the T effector memory (TeM) and T 
terminally-differentiated effector (TeMRA) pools. As such, the effect of 
immune activation on the dynamics of blood Tn, TCM, TeM and TeMRA 
subsets is far from understood and may differ greatly between diabetic 
and non-diabetic subjects. 
In this study, we examined quantitative changes in MDC, PDC, 
monocyte, CD4+T and CD8+T cell compartments and assessed 
cytokine expression in CD4+T cells and CD8+T cells from diabetic 
children relative to sibling and age-matched controls. To do this, we 
used minimally manipulated leukocytes from erythrocyte-lysed fresh 
blood stained with antibodies to cell surface markers, cytokines and the 
transcription factor Foxp3. Stained leukocytes were then assessed by 
polychromatic five- to seven-color flow cytometry which allowed the 
dissection of multiple subsets within the circulating DC, monocyte and 
T cell compartments. 
Materials and Methods
Study subjects 
Children with T1D (mean ± standard deviation [SD], hemoglobin 
A1c of 8.1% ± 2.9%, insulin dosage of 0.95 ± 0.24 unit/Kg/day) and 
their siblings with normal blood glucose levels were recruited from 
the Queensland Diabetes Centre at the Mater Children’s Hospital. 
Age-matched, non-diabetic controls were recruited from children 
awaiting elective operations, and their blood samples were collected 
T1D Siblings Controls Significance Value
Number 26 32 29
&Male 15 (58%) 16 (50%) 14 (48%) 0.43
#Age (yrs) 12.28 (6.18) 11.75 (5.40) 8.18 (7.60) 0.25
 #Disease duration (yrs) 2.93 (4.14)
Autoantibody
&GADA 15 (83%) 4 (14%)
&IA-2A 14 (82%) 1 (4%)
&GADA&IA-2A 14 (82%) 1 (4%)
Blood Count (x106/ml)
#RBC 4790 (200) 4670 (330) 4560 (440) a*
#WBC 6.30 (1.37) 6.23 (1.34) 9.05 (3.14) a***, b***
#Lymphocytes 2.62 (0.89) 2.58 (0.65) 3.64 (1.04) a***, b***
#Monocytes 0.49 (0.12) 0.48 (0.10) 0.64 (0.25) a**, b***
#Neutrophils 2.87 (0.98) 2.85 (1.06) 4.34 (2.33) a**, b**
#Eosinophils 0.20 (0.14) 0.14 (0.22) 0.25 (0.36) 0.26
#Basophils 0.04 (0.04) 0.05 (0.04) 0.06 (0.04) 0.13
&Categorical variables are presented using counts and percentages. #Continuous variables: WBC, Neutrophils, Lymphocytes and Monocytes are presented as mean 
(SD); Age, Disease duration, RBC, Eosinophils and Basophils are expressed as median (interquartile range). Denote: a, difference between T1D children and controls; 
b, difference between siblings and controls. *, P < 0.05; **, P < 0.01; *** P < 0.001.
Table 1: Characterisation of study subjects.
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prior to surgery. Characteristics of all participants are shown in Table 
1. Venous blood samples were collected in eDTA (K2e) Vacutainer 
tubes, processed for full blood counts on an automated blood analyzer 
(CeLL-DYn Sapphire or CeLL-DYn 3200, Abbott Diagnostics, 
USA) and analyzed by polychromatic flow cytometry within 12 hours 
of collection. This study was approved by the Mater Health Services 
Human Research ethics Committee and all subjects participated after 
informed consent was given by the parents/guardians and assent by 
the children.
Cell staining and polychromatic flow cytometry
All staining protocols were performed using erythrocyte-lysed 
fresh blood. Monoclonal antibodies (mAb) were purchased from BD 
Bioscience (Sydney, nSW) unless otherwise specified. The protocol 
for surface antigen staining used 50 µl of whole blood. The Foxp3 and 
cytokine expression protocols used 200 µl of whole blood in which 
surface antigen staining was followed by fixation, permeabilization 
(Fixation&Permeabilization buffer, eBioscience, Sydney, nSW) and 
intracellular staining for Foxp3 or cytokines. 
A seven-color flow cytometry assay was used to analyze total MDC 
(CD11c+MDC) and their subsets (CD16+CD141-MDC, CD16-CD141-
MDC and CD16-CD141+MDC) and PDC (CD123+PDC) in the same 
Trucount tube (BD Bioscience). This assay used a mAb mix consisting 
of CD45-APCH7, CD3, 19, 20, 14, 56, 34-FITC, HLA-DR-PeCy7, 
CD11c-APC, CD123-PercPCy5.5, CD141-Pe (Miltenyi Biotech, 
Sydney, nSW) and CD16-Pacific Blue. Total CD14+ monocytes, 
B cells and their respective subsets (CD16+ and CD16- monocytes; 
CD27+ and CD27- B cells) were analyzed in the same Trucount tube 
using a five-color flow cytometry assay with a mAb mix consisting 
of CD45-APCH7, CD14-FITC, CD20-APC, CD27-Pe and CD16-
Pacific Blue. Data relating to B cells have not been included in this 
study. CD4+T and CD8+T cell subsets: Tn cells (CD45RO-CD62L+), 
TCM cells (CD45RO+CD62L+), TeM cells (CD45RO+CD62L-) and TeMRA 
cells (CD45RO-CD62L-) were defined in the same FACS tube using a 
five-color flow cytometry assay with a mAb mix consisting of CD45-
APCH7, CD4-FITC, CD8-PeCy7, CD45RO-Pe and CD62L-APC. 
TReg cells (CD4+CD25+CD127lo/-) were defined using a five-color flow 
cytometry assay with a mAb mix consisting of CD45-APCH7, CD4-
FITC, CD8-PeCy7, CD127-Pe and CD25-APC. 
A five-color immunostaining protocol was used to analyze 
intracellular Foxp3 expression in CD4+T cells (CD4+Foxp3+ TReg cells) 
and cytokine expression in CD4+T and CD8+T cells. This protocol used 
a mAb mix consisting of CD45-APCH7, CD4-FITC, CD8-PeCy7, 
CD25-APC in conjunction with either Foxp3-Pe (Foxp3 Assay staining 
kit, eBioscience), IL-17A-Pe, IL-2-Pe (eBioscience), IFn-γ-Pe, TgF-
β-Pe (IQ products, groningen, the netherlands), IL-6-Pe, TnF-α-Pe, 
IL-10-Pe or IL-1β-Pe. 
Samples that were stained in Trucount tubes were acquired within 
2 hours and in FACS tubes within 12 hours of staining (LSR II Flow 
Cytometer, BD). Data were analyzed using CellQuest (BD Bioscience) 
and FlowJo (TreeStar, Ashland, OR) software. The absolute numbers 
of MDC, PDC and monocytes (cells/µl blood) were calculated from 
the data acquired from Trucount tubes [3]. Proportions of: Tn, TCM, 
TeM, TeMRA, TReg cells, and CD4+T and CD8+T effector cells expressing 
specific cytokines were calculated from FACS tubes. 
Statistical analysis 
Characteristics of study subjects are presented as categorical and 
continuous variables (Table 1). Categorical variables are presented 
using counts and percentages. Fisher’s exact test or the chi-squared test 
was used to compare categorical variables between the three groups 
of subjects. Continuous variables are presented using mean and SD 
or median and interquartile range depending on the normality of 
the data (assessed using the Shapiro-Wilk normality test with results 
confirmed using visual inspection of histograms). Analysis of variance 
or Kruskal-Wallis test was used to compare continuous variables 
between the three groups of subjects applying Bonferroni’s adjustment 
for multiple comparisons in post-hoc testing using Tukey’s and Dunn’s 
tests respectively. Spearman’s correlation test was used to analyze 
the association between clinical variables (age, age of diagnosis and 
disease duration) and continuous variables (TReg cells and cytokine 
expressing TeM cells) or association between continuous variables (TReg 
cells and cytokine expressing TeM cells). Analysis was performed using 
graphPad Prism 5.0 software (San Diego, California). Differences were 
considered statistically significant at the 0.05 level. 
Results
Numbers of CD11c+CD16+ MDC and PDC are decreased in 
diabetic children and their siblings
We previously reported decreased blood MDC and PDC numbers 
in diabetic children [3], however, whether this finding differentiated 
diabetic children from their siblings was not assessed. In this study, 
we compared the absolute number of multiple DC subsets in blood 
samples of diabetic children, their siblings and age-matched controls 
(Figure 1). In contrast to our earlier report, which employed four-
color flow cytometry [3], this study used seven-color flow cytometry, 
again, in conjunction with Trucount beads. This increased the data-
capturing throughput, and more importantly, enabled concurrent 
analysis of the absolute numbers of three subsets of CD11c+MDC 
(CD16+MDC, CD16-CD141-, CD16-CD141+) and CD123+PDC in the 
same reaction tube (Figure 1A, representative dot plots). As such, 
this approach eliminated factors that affect accurate quantification of 
DC subsets from multiple reaction tubes [3,17]. Using this improved 
analysis, we found that both diabetic children and siblings displayed a 
similar decrease in the total numbers of CD11c+MDC and CD123+PDC 
compared to controls (Figure 1B). The decrease in total CD11c+MDC 
number was specifically a result of a decreased CD16+MDC number 
(Figure 1B). The comparable age range between cohorts of diabetic 
children, siblings and controls (Figure 1B) ruled out the possibility that 
age differences contributed to the observed decrease in CD16+MDC 
and PDC numbers in diabetic children and siblings. In contrast to 
CD16+MDC and PDC, the numbers of CD16-CD141-MDC and CD16-
CD141+MDC were comparable across the three study groups (Figure 
1B). These findings suggest that a decrease in CD16+MDC and PDC 
lineages is common to both diabetic children and their siblings. 
Number of CD14+CD16+ monocytes is decreased in diabetic 
children and their siblings 
We hypothesized that monocytes, which are developmentally 
connected to DC [18], would also be altered in diabetic children or their 
siblings. We initially used full blood counts to examine the absolute 
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number of total blood monocytes in larger cohorts of diabetic children, 
siblings and controls (Figure 2A). This experimental approach revealed 
a decrease in total blood monocyte number in diabetic children and 
siblings compared to controls (Figure 2A). These cohorts of diabetic 
children, siblings and controls were comparable in age range (Figure 
2A), therefore, ruling out the possibility that age differences contributed 
to the observed decrease in monocytes in diabetic children and 
siblings. In a smaller cohort of diabetic children, siblings and controls, 
total monocytes and their CD14+CD16+ and CD14+CD16- subsets were 
assessed by polychromatic flow cytometry (Figure 2B). This analysis 
revealed that the CD16+ monocyte subset exclusively accounted for 
the decrease in the number of total monocytes, while the number of 
CD16- monocytes was comparable between diabetic children, siblings 
and controls (Figure 2B). The subjects in these smaller cohorts were 
again comparable in age range (Figure 2B), therefore, ruling out the 
possibility of age as a contributing factor to the observed decrease in 
CD14+CD16+ monocytes in diabetic children and siblings. These data 
suggest that diabetic children and their siblings share a decrease in 
CD14+CD16+ monocytes, similar to what was noted for CD16+MDC 
and PDC. 
Proportions of TN, TCM, TeM, TeMRA and TReg cells are similar in 
diabetic children and their siblings
We reasoned that in diabetic children, ongoing immune activation 
could alter the dynamics of Tn, TCM, TeM and TeMRA and T Reg cells 
[9,19]. To address this possibility, the proportions of Tn, TCM, TeM, and 
TeMRA cells within the CD4+T and CD8+T cell compartments and the 
proportion of TReg cells within the CD4+T cell compartment of diabetic 
children, their siblings and controls were compared. The CD4+T and 
CD8+T cell compartments of diabetic children, siblings and controls 
contained similar proportions of Tn, TCM, TeM, and TeMRA cells (Figure 
3A). Proportion of TReg cells, assessed by two commonly used marker 
combinations (CD4+CD25+CD127lo/- and CD4+Foxp3+) [20,21], were 
also comparable in diabetic children, siblings and controls (Figure 
3B). In all three subject groups, there was no association between TReg 
cells defined as CD4+CD25+CD127lo/- and CD4+Foxp3+ cells (data not 
shown), in disagreement to a previous report suggesting an association 
between CD4+CD25+CD127lo/- T cells and CD4+Foxp3+ T cells in adult 
controls [20]. 
We also performed association analyses in diabetic children 
correlating age (at time of sampling), age of diagnosis and disease 
duration with the proportions of CD4+CD25+CD127lo/- and CD4+Foxp3+ 
TReg cells. In diabetic children, age and age of diagnosis was associated 
with an increase in the proportion of CD4+CD25+CD127lo/- TReg cells 
but was not associated with the proportion of CD4+Foxp3+ TReg cells 
(Figure 3C). In contrast, disease duration was not associated with the 
proportion of CD4+CD25+CD127lo/- or CD4+Foxp3+ TReg cells (Figure 
3C). Overall, these results suggest that disease development in diabetic 
children does not influence the dynamics of blood Tn, TCM, TeM, TeMRA 
and TReg cells. In addition, our study indicates that in diabetic children, 
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an age-related increase in the proportion of CD4+CD25+CD127lo/- TReg 
cells exists.
expansion of CD4+T cells expressing IL-17 differentiates 
diabetic children from their siblings
Despite our finding that diabetic children and their siblings did not 
display a difference in the proportion of specific subsets among CD4+T 
and CD8+T cells, it is clear that not all such T cells are equivalent 
in diabetic children and their non-diabetic siblings and, therefore, 
different effector functions should be elicited by such T cells. As a 
result, we proposed that function rather than quantity of T cells may 
represent the means by which T cells differentiate diabetic children 
from their non-diabetic siblings. In this study, functional attributes of 
CD4+T and CD8+ T cells from diabetic children, siblings and controls 
were assessed by expression of IL-17, IL-2, IFn-γ, IL-6, TgF-β, TnF-α, 
IL-10 and IL-1β cytokines. A discrete fraction of circulating CD4+T 
cells expressing IL-17 differentiated diabetic children from siblings and 
controls (Figure 4A, Supplementary Figure 1). In diabetic children, 
these CD4+T cells expressing IL-17 were accompanied by expansion 
of CD4+T and CD8+T cells expressing IL-2 (Figure 4A, Supplementary 
Figure 1). 
We next investigated the association between the proportion 
of CD4+T cells expressing IL-17 and the proportion of TReg cells, as 
these two categories of CD4+ T cells may show contrasting functions 
during immune responses [22]. In diabetic children, there was no 
association between the proportion of CD4+T cells expressing IL-17 
and the proportion of TReg cells defined as CD4+CD25+CD127lo/- and 
CD4+Foxp3+ cells (data not shown). Also, there was no association 
between the proportion of CD4+T cells expressing IL-17 and the 
proportion of CD4+T or CD8+T cells expressing IL-2. In addition, there 
was no association between age, age of diagnosis or disease duration 
and the proportion of CD4+T cells expressing IL-17, or the proportion 
of CD4+T and CD8+T cells expressing IL-2 (Figure 4B). 
Discussion
This study compared MDC, PDC, monocyte, CD4+T and CD8+T 
cell compartments in diabetic children, their siblings and controls, 
as well as immune activation as assessed by cytokine expression in 
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CD4+T and CD8+T cells. This approach was based on the supposition 
that identified blood immune cell abnormalities may explain the 
progression of autoimmunity from non-diabetic siblings to diabetic 
children. Diabetic children and siblings living in the same family were 
recruited to minimize differences in age and environmental factors 
which could confound the immunological assessment of blood cells 
[3,23]. This study demonstrates two main points; firstly, diabetic 
children and siblings have decreased numbers of circulating blood 
immune cells involving CD16+MDC, PDC and CD16+ monocytes, 
and secondly, diabetic children have an expanded pool of CD4+T cells 
expressing IL-17 which differentiates diabetic children from their 
siblings and controls.
In humans, a quantitative deficiency in blood DC and monocyte 
lineages is a rare occurrence and has traditionally been interpreted as 
a consequence of disease, in particular to certain infections [24] and 
malignancy [17]. Our data suggest that a decrease in blood CD16+MDC, 
PDC and CD16+ monocyte numbers is not specific to disease status, 
rather it is common to both diabetic children and their healthy non-
diabetic siblings and may signify a shared genetic or environmental 
origin. As such, a decrease in blood CD16+MDC, PDC and CD16+ 
monocytes is not sufficient by itself for disease development, as the vast 
majority of siblings (> 90%) do not develop T1D [25]. Therefore, the 
contribution of a quantitative defect in peripheral blood CD16+MDC, 
PDC and CD16+ monocytes in driving T1D pathology remains unclear. 
However it is worth noting that blood CD16+MDC, PDC and CD16+ 
monocytes belong to the family of blood CD11c+ myeloid cells which 
express the β cell-autoantigen proinsulin [5], a target autoantigen in 
T1D. Although expression of β cell-autoantigen(s) on discrete blood 
DC and monocyte subsets has yet to be defined, it is possible that 
CD16+MDC, PDC and CD16+ monocytes may also be an important 
source of β cell-autoantigen(s), and decreased numbers of these cells 
may impact on peripheral tolerance. 
It is unclear what causes the decrease in CD16+MDC, PDC and 
CD16+  monocyte number in diabetic children and their siblings, 
nonetheless, it is possible that a dysregulated development from 
myeloid precursors or a reduced lifespan within the circulation can 
contribute. With regard to dysregulated myeloid cell development, the 
highly conserved transcription factor Hox11 is of particular interest, 
as its over expression can immortalize or reprogram bone-marrow 
derived progenitors [26,27]. A recent study in nOD mice suggests 
that Hox11-derived organs are prone to developing primary structural 
and functional defects largely independent of autoimmune-mediated 
destruction of the pancreas [28]. It is equally possible that in diabetic 
children and their siblings, the lifespan of blood CD16+MDC, PDC and 
CD16+ monocytes is shortened due to their migration into the extra-
vascular space. Consistent with this concept, DC and macrophages are 
attracted to the pancreas of nOD mice in the early stages of insulitis 
prior to disease onset [29]. Further studies are needed to address the 
mechanisms causing the decreased number of CD16+MDC, PDC 
and CD16+  monocyte in diabetic children and their siblings and how 
this may promote the breakdown of islet β cell tolerance. Of interest 
is our observation that diabetic children and siblings have a reduced 
numbers of neutrophils and lymphocytes in addition to the decreased 
CD16+MDC, PDC and CD16+ monocyte number (Table 1). In contrast, 
the red blood cell count was increased in diabetic children when 
compared to controls (Table 1). Our study complements previous 
reports suggesting decreased lymphocyte number (lymphopenia) in 
patients with autoimmune diseases [30], and decreased lymphocytes, 
myeloid cells and DC but not erythromyeloid cells in nOD mice before 
the onset of insulitis [31,32].
In diabetic subjects, chronic immune activation would be expected 
to influence the dynamics of blood CD4+ T and CD8+ T cell subsets, 
in particular, favoring an increased proportion of pathogenic TeM cells 
[16,33,34]. In addition, with the expansion of pathogenic TeM cells 
and the progression of β cell autoimmunity, a decreased number or 
diminished function of blood TReg cells might occur [9,19]. However, 
we found that the CD4+ T and CD8+ T cell subsets demarked as Tn, TCM, 
TeM and TeMRA cells were comparable in diabetic children, siblings and 
controls. There were also no detectable differences in the proportion 
of TReg cells defined as CD4+CD25+CD127lo/- and CD4+Foxp3+ T cells 
between the three groups, a finding similar to other studies investigating 
diabetic subjects [11-13]. However, our study identified a strong 
association between the age at time of sampling and age of diagnosis 
and the proportion of CD4+CD25+CD127lo/- TReg cells, suggesting in 
line with a previous study [19] that age matching between diabetic and 
non-diabetic subjects is required for the immunological assessment 
of blood TReg cells. This age-related increase in CD4+CD25+CD127lo/- 
TReg cells in diabetic children can mask any effect that disease duration 
may have on dynamics of blood T cells subsets including TReg cells. 
Also, in diabetic children and non-diabetic children (siblings and 
controls), the lack of association between CD4+CD25+CD127lo/- T cells 
and CD4+Foxp3+ T cells, which are categorically accepted as TReg cells 
in adult subjects [20,21], calls into question the use of these marker 
combinations in assessing TReg cells in pediatric subjects.
Although T cell subsets are comparable in diabetic children, 
their siblings and controls, we observed an expansion of CD4+ T cells 
expressing IL-17 exclusively in diabetic children. Two recent articles 
suggest that CD4+T cells from diabetic children are capable of IL-
17 production upon in vitro activation [33,34]. However, our study 
represents the first report that circulating CD4+T cells expressing 
IL-17 are detectable directly in unstimulated erythrocyte-lysed fresh 
blood samples of diabetic children. We detected circulating CD4+T 
cells expressing IL-17 in children with established T1D (1.3-10.9 
yrs), suggesting that these cells may be associated with continuing 
progression of β cell autoimmunity. Certainly in inflammatory 
conditions, circulating CD4+T cells expressing IL-17 contribute to the 
proinflammatory responses, and in diabetes they may promote human 
islet cell destruction [33]. Recent studies also suggest that in diabetic 
children, distinction of Th17 immunity is not absolute, and IL-17 
expressing cells may exhibit an intermediate pattern of cytokine and 
transcription factor production. For example, CD4+T cells expressing 
IL-17 coexpress IFn-γ and Foxp3, biomolecules originally described as 
being restricted to Th1 and TReg cells respectively [33,34]. Studies using 
nOD mice also emphasize that coexpression of IL-17 and IFn-γ by 
pathogenic T cells contributes to the effector phase of disease [35,36]. In 
our study design we did not explore coexpression of IFn-γ and Foxp3 
on CD4+T cells expressing IL-17, and it will be of interest to define 
whether distinctive Th17 patterns differentiate diabetic children from 
their siblings. Further research is required to establish whether these 
blood CD4+T cells expressing IL-17 are capable of directly reacting 
against self-tissue, including islet β cells. Such insights may provide the 
rationale for strategies aimed at selective elimination of tissue (islet) 
autoreactive T cells. 
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Increased proportions of CD4+T and CD8+T cells expressing IL-2 
were also detected in diabetic children. The role of IL-2 in regulating 
autoimmunity appears to be complex [37,38]. On one side, IL-2 can 
prevent autoimmunity through the generation and maintenance 
of TReg cells [37]. However, IL-2 has also been reported to promote 
some aspects of autoimmunity through stimulating T cell activation, 
perhaps in the same way that it promotes T cell adaptive immunity 
against foreign antigen [38]. evidence from a human study supports 
a role for IL-2 in the development of IL-17 cells from TReg cells [39]. 
nevertheless, our data suggest that in diabetic children, combined IL-2 
and IL-17 responses contribute to the inflammatory environment that 
sustains β cell damage and the clinical onset of T1D. 
Our results, suggest that a decrease in circulating blood immune 
cells, in particular CD16+MDC, PDC and CD16+  monocytes, by itself is 
not sufficient for the development of T1D. However, the combination 
of decreased circulating immune cells and IL-17 proinflammatory 
responses appears to be important for the breakdown of peripheral 
tolerance and ultimately, disease expression in diabetic children.
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